Sökning: "MYCN"
Visar resultat 36 - 40 av 53 avhandlingar innehållade ordet MYCN.
36. The role of KIF1Bß in neuroblastoma tumour suppression during sympathetic neuron development
Sammanfattning : Neuroblastoma, the most common extra-cranial childhood tumour, is believed to arise from precursor cells of the sympathetic nervous system (neuroblasts). Hemizygous loss of chromosome 1p36 strongly correlates with poor prognosis in neuroblastoma and the 1p36 gene KIF1Bβ has been proposed to be a pathogenic target of this deletion. LÄS MER
37. Molecular characterization of neuroblastoma tumors - a basis for personalized medicine
Sammanfattning : Neuroblastoma is a very heterogeneous tumor, with a clinical course ranging from spontaneous regression to aggressive tumor growth. A proper stratification of the patients into different risk groups is therefore important in order to provide the most suitable treatment for each patient. LÄS MER
38. Searching for Synergy : Radiosensitization of 177Lu-DOTATATE
Sammanfattning : Cancers presents a major health challenge, and there is a pressing need to develop new therapeutic strategies. Surgery, chemotherapy and radiation are the most commonly used treatments for cancer today. Radiation can be given as targeted radionuclide therapy (TRT), i.e. LÄS MER
39. Of Mice and MYC : Modelling Medulloblastoma
Sammanfattning : Brain tumours are the leading cause of cancer-related paediatric deaths, with medulloblastoma (MB) being the most common malignant paediatric brain tumour. MB is stratified into four major subgroups – WNT, SHH, Group 3, and Group 4, nomenclature defined by key pathways and drivers involved within each subgroup. LÄS MER
40. Retinoids in experimental neuroblastoma therapy
Sammanfattning : Retinoids are analogues of vitamin A, with documented activity against various malignant cell types. Neuroblastoma is a childhood tumour of the sympathetic nervous system that shows a complex clinical and biological heterogeneity, often with poor outcome despite intensive multimodal therapy. LÄS MER